Pyrimidine-Based Compounds in Tuberculosis Management: A Review of their Biological and Medicinal Importance
- 1 February 2026
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 22 (2) , 127-138
Abstract
Pyrimidine derivatives are a class of chemically and biologically active heterocyclic compounds promising for developing anti-tubercular, anti-viral, anti-malarial, anti-inflammatory, and enzyme-inhibiting drugs. To cure TB, scientists were driven to establish novel pyrimidine derivatives. The main objective of the current review is to identify and develop new pyrimidine moiety- containing derivatives that have been assessed for their structure-activity relationship (SAR). Several drug-resistant MTB infections have emerged and spread worldwide, which has rendered first-line medication ineffective. It is crucial to develop new anti-TB drugs that are extremely effective against both drug-sensitive and drug-resistant TB. The development of pyrimidine therapeutic methods will thus benefit from the current review. Three medications-GSK-286, TBA-7371, and SPR-720 are now undergoing clinical testing. This study aims to emphasize the structural variety of anti-tuberculosis pyrimidine-containing compounds by providing an overview of current developments in drug discovery investigations.Keywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology, India (DST-WOS-A)
- Department of Science and Technology, Ministry of Science and Technology, India (CS-13/WOS-A/2021)
This publication has 67 references indexed in Scilit:
- Synthesis of 6-dialkylaminopyrimidine carboxamide analogues and their anti-tubercular propertiesMedicinal Chemistry Research, 2024
- Synthesis, biological evaluation and molecular docking study of pyrimidine linked thiazolidinedione derivatives as potential antimicrobial and antitubercular agentsBioorganic & Medicinal Chemistry Letters, 2024
- Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agentsMolecular Diversity, 2022
- Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discoveryBioorganic Chemistry, 2021
- Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicalsMedcomm, 2021
- Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studiesBioorganic Chemistry, 2020
- Antituberculosis Agents2017
- A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisInfectious Diseases and Therapy, 2013
- Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2′-‘up’ fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitorsBioorganic & Medicinal Chemistry, 2012
- De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathwaysCellular and Molecular Life Sciences, 2003